Skip to content

Study · Non-randomized trial · 2018

8 results

Pramlintide: The Effects of a Single Drug Injection on Blood Phosphatidylcholine Profile for Alzheimer's Disease.

Tao Q, Zhu H, Chen X, Stern RA, Kowall N, Au R, Blusztajn JK, Qiu WQ

Journal of Alzheimer's disease : JAD1 Jan 2018Cited by 5 (Europe PMC)

PMID29480193 (opens in a new tab)PMCIDPMC5956916 (opens in a new tab)DOI10.3233/jad-170948 (opens in a new tab)PepBankPUB-29480193
Source linkPubMedAsk about this study
Jump to 8 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study8

2 results from studies that gave the peptide. 2 results from people.

  1. 01HumanNon-randomized trialActivity measurement

    In non-diabetic subjects, a single pramlintide injection altered blood levels of 7 phosphatidylcholines.

    In plain wordsIn non-diabetic people, one pramlintide injection changed blood levels of 7 phosphatidylcholines.

    Peptide
    Pramlintide (Symlin)
    Outcome
    MixedBlood phosphatidylcholine changes after fasting challenge
    Study

    n: not reported in source

    Outcome group
    Lipids · Nervous system and cognition
    Studied dose
    60 mcg · subcutaneous · Single injectionAs given in this study (human).

    Measurements

    Phosphatidylcholines altered in blood
    7 PCs
    Single pramlintide injection, fasting, p<0.05

    Source sentences

    Summary
    A single injection of pramlintide altered the levels of 7 PCs in the blood, while a pramlintide injection plus food modulated the levels of 10 PCs in the blood (p < 0.05).
    1 context sentence
    Summary · context
    Non-diabetic subjects with cognitive status were administered a single subcutaneous injection of 60 mcg of pramlintide under fasting condition.
  2. 02HumanNon-randomized trialActivity measurement

    In non-diabetic subjects, pramlintide injection plus food altered blood levels of 10 phosphatidylcholines.

    In plain wordsIn non-diabetic people, pramlintide injection plus food changed blood levels of 10 phosphatidylcholines.

    Peptide
    Pramlintide (Symlin)
    Outcome
    MixedBlood phosphatidylcholine changes with food
    Study

    n: not reported in source

    Outcome group
    Lipids · Nervous system and cognition
    Studied dose
    Dose not stated

    Measurements

    Phosphatidylcholines modulated in blood
    10 PCs
    Pramlintide injection plus food, p<0.05

    Source sentences

    Summary
    A single injection of pramlintide altered the levels of 7 PCs in the blood, while a pramlintide injection plus food modulated the levels of 10 PCs in the blood (p < 0.05).
    1 context sentence
    Summary · context
    Non-diabetic subjects with cognitive status were administered a single subcutaneous injection of 60 mcg of pramlintide under fasting condition.

Studies that did not test the peptide alone6

In this study, Pramlintide (Symlin) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Pramlintide (Symlin).

  1. 03HumanNot a test of Pramlintide (Symlin) aloneNon-randomized trialOther

    After pramlintide challenge, subjects with MCI had lower levels of 2 phosphatidylcholines than controls.

    In plain wordsAfter pramlintide challenge, people with MCI had lower levels of 2 phosphatidylcholines than controls.

    Peptide
    Pramlintide (Symlin)
    Outcome
    DecreasePhosphatidylcholine levels in MCI after challenge
    Study

    n: not reported in source

    Comparator
    Controls
    Outcome group
    Lipids · Nervous system and cognition

    Measurements

    Phosphatidylcholines lower than controls
    2 PCs
    MCI after pramlintide challenge

    Source sentences

    Summary
    The levels of 2 PCs in MCI and 12 PCs in AD in the pramlintide challenge were significantly lower than the ones in controls.
    1 context sentence
    Summary · context
    Non-diabetic subjects with cognitive status were administered a single subcutaneous injection of 60 mcg of pramlintide under fasting condition.

    In this study, Pramlintide (Symlin) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Pramlintide (Symlin).

  2. 04HumanNot a test of Pramlintide (Symlin) aloneNon-randomized trialOther

    After pramlintide challenge, subjects with AD had lower levels of 12 phosphatidylcholines than controls.

    In plain wordsAfter pramlintide challenge, people with AD had lower levels of 12 phosphatidylcholines than controls.

    Peptide
    Pramlintide (Symlin)
    Outcome
    DecreasePhosphatidylcholine levels in AD after challenge
    Study

    n: not reported in source

    Comparator
    Controls
    Outcome group
    Lipids · Nervous system and cognition

    Measurements

    Phosphatidylcholines lower than controls
    12 PCs
    AD after pramlintide challenge

    Source sentences

    Summary
    The levels of 2 PCs in MCI and 12 PCs in AD in the pramlintide challenge were significantly lower than the ones in controls.
    1 context sentence
    Summary · context
    Non-diabetic subjects with cognitive status were administered a single subcutaneous injection of 60 mcg of pramlintide under fasting condition.

    In this study, Pramlintide (Symlin) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Pramlintide (Symlin).

  3. 05HumanNot a test of Pramlintide (Symlin) aloneNon-randomized trialOther

    After pramlintide challenge, some phosphatidylcholines were associated only with Aβ, whereas others were associated with both Aβ and total tau.

    In plain wordsAfter pramlintide challenge, some phosphatidylcholines were linked only to Aβ, whereas others were linked to both Aβ and total tau.

    Peptide
    Pramlintide (Symlin)
    Outcome
    Not applicablePhosphatidylcholine associations with AD biomarkers
    Study

    n: not reported in source

    Outcome group
    Metabolic pathways and metabolomics · Nervous system and cognition

    Source sentences

    Summary
    We found that while some PCs were associated with only Aβ levels, other PCs were associated with both Aβ and t-tau levels.
    1 context sentence
    Summary · context
    Non-diabetic subjects with cognitive status were administered a single subcutaneous injection of 60 mcg of pramlintide under fasting condition.

    In this study, Pramlintide (Symlin) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Pramlintide (Symlin).

  4. 06HumanNot a test of Pramlintide (Symlin) aloneNon-randomized trialOther

    The combined post-challenge phosphatidylcholine and AD biomarker analysis had an AUC of 0.9799 for MCI versus controls.

    In plain wordsThe combined post-challenge phosphatidylcholine and AD biomarker analysis had an AUC of 0.9799 for MCI versus controls.

    Peptide
    Pramlintide (Symlin)
    Outcome
    Not applicableDiagnostic AUC for MCI versus controls
    Study

    n: not reported in source

    Comparator
    Controls
    Outcome group
    Diagnostic test performance · Nervous system and cognition

    Measurements

    AUC
    0.9799 unitless
    MCI versus controls

    Source sentences

    Summary
    A receiver operating characteristic analysis of the PCs was combined with the Aβ and t-tau data to produce an area under the curve predictive value of 0.9799 between MCI subjects and controls, 0.9794 between AD subjects and controls, and 0.9490 between AD and MCI subjects.
    1 context sentence
    Summary · context
    Non-diabetic subjects with cognitive status were administered a single subcutaneous injection of 60 mcg of pramlintide under fasting condition.

    In this study, Pramlintide (Symlin) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Pramlintide (Symlin).

  5. 07HumanNot a test of Pramlintide (Symlin) aloneNon-randomized trialOther

    The combined post-challenge phosphatidylcholine and AD biomarker analysis had an AUC of 0.9794 for AD versus controls.

    In plain wordsThe combined post-challenge phosphatidylcholine and AD biomarker analysis had an AUC of 0.9794 for AD versus controls.

    Peptide
    Pramlintide (Symlin)
    Outcome
    Not applicableDiagnostic AUC for AD versus controls
    Study

    n: not reported in source

    Comparator
    Controls
    Outcome group
    Diagnostic test performance · Nervous system and cognition

    Measurements

    AUC
    0.9794 unitless
    AD versus controls

    Source sentences

    Summary
    A receiver operating characteristic analysis of the PCs was combined with the Aβ and t-tau data to produce an area under the curve predictive value of 0.9799 between MCI subjects and controls, 0.9794 between AD subjects and controls, and 0.9490 between AD and MCI subjects.
    1 context sentence
    Summary · context
    Non-diabetic subjects with cognitive status were administered a single subcutaneous injection of 60 mcg of pramlintide under fasting condition.

    In this study, Pramlintide (Symlin) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Pramlintide (Symlin).

  6. 08HumanNot a test of Pramlintide (Symlin) aloneNon-randomized trialOther

    The combined post-challenge phosphatidylcholine and AD biomarker analysis had an AUC of 0.9490 for AD versus MCI.

    In plain wordsThe combined post-challenge phosphatidylcholine and AD biomarker analysis had an AUC of 0.9490 for AD versus MCI.

    Peptide
    Pramlintide (Symlin)
    Outcome
    Not applicableDiagnostic AUC for AD versus MCI
    Study

    n: not reported in source

    Comparator
    MCI subjects
    Outcome group
    Diagnostic test performance · Nervous system and cognition

    Measurements

    AUC
    0.949 unitless
    AD versus MCI

    Source sentences

    Summary
    A receiver operating characteristic analysis of the PCs was combined with the Aβ and t-tau data to produce an area under the curve predictive value of 0.9799 between MCI subjects and controls, 0.9794 between AD subjects and controls, and 0.9490 between AD and MCI subjects.
    1 context sentence
    Summary · context
    Non-diabetic subjects with cognitive status were administered a single subcutaneous injection of 60 mcg of pramlintide under fasting condition.

    In this study, Pramlintide (Symlin) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Pramlintide (Symlin).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.